Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-centre, Randomised, Double-blind, Placebo-controlled, Single Dose, Dose Escalation Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-0000-2021 Administered Intravenously and Subcutaneously to Healthy Male Subjects and Haemophilia Subjects

NCT01228669 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT01228669
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01228669 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-centre, Randomised, Double-blind, Placebo-controlled, Single Dose, Dose Escalation Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-0000-2021 Administered Intravenously and Subcutaneously to Healthy Male Subjects and Haemophilia Subjects
Lead sponsor
Novo Nordisk A/S
Phase
Phase 1
Overall status
Completed
Start date
October 25, 2010
Completion date
September 10, 2012
Enrollment
52 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

congenital bleeding disorder, haemophilia a, haemophilia b, healthy